26.09.2011,
in
Soci 2011
HELSINN GROUP
HELSINN GROUP AND EISAI INC. ANNOUNCE START OF PHASE III CLINICAL PROGRAM OF ORAL FIXED-DOSE COMBINATION OF NETUPITANT/ PALONOSETRON (300 mg/0.50 mg) FOR PREVENTION OF CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV)
20.09.2011,
in
Soci 2011
Helsinn Therapeutics Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
06.09.2011,
in
Soci 2011
Cerbios confirmed by D&B in the top 500 Swiss companies with Risk Indicator 1
In June 2011, Cerbios received from Dun & Bradstreet the newly issued Rating Certificate confirming Cerbios as a company with Risk Indicator of 1 (D&B Risk Indicators range from 1, minimum risk, to 4, high risk)
30.08.2011,
in
Soci 2011
La nuova passerella di collegamento della sede Helsinn, tra crescita e innovazione
Struttura architettonica in acciaio e vetro, unica nel suo genere nel luganese unisce i due stabili della sede centrale del Gruppo
18.05.2011,
in
Soci 2011
Cerbios founder and former president, received an honorary doctorate from St. Petersburg’s Society of Oncologists
To his surprise, last March 5,Dr. Attilio Melera, Honorary Chairman of the Board of Cerbios-Pharma S.A.(henceforth "Cerbios") received the Doctorate Honoris Causa from the Scientific Society of Oncologists of St. Petersburg
12.05.2011,
in
Soci 2011
Helsinn Group Invests in Thorne Research
Helsinn Group makes an equity investment for a minority interest in Thorne Research, Inc. and plans to jointly commercialize nutritional supplement products with initial focus on meeting the needs of people living with cancer
04.04.2011,
in
Soci 2011
Il Gruppo Helsinn punta su Biasca
Nuovi investimenti negli impianti chimico-farmaceutici del gruppo ticinese
24.01.2011,
in
Soci 2011
